Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
INDP | US
0.02
1.08%
Healthcare
Biotechnology
30/06/2024
09/03/2026
1.87
1.81
1.88
1.65
Indaptus Therapeutics Inc. a clinical biotechnology company develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma hepatocellular colorectal and pancreatic tumors as well as chronic hepatitis B virus and human immunodeficiency virus infection which is in Phase 2 clinical trial. The company was formerly known as Intec Parent Inc. and changed its name to Indaptus Therapeutics Inc. in August 2021. Indaptus Therapeutics Inc. is headquartered in New York New York.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
75.7%1 month
77.2%3 months
121.4%6 months
130.2%-
-
2.50
0.02
0.02
1.03
-
-
-16.48M
19.07M
19.07M
-
-
-
-
-127.04
1.54
0.45
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.53
Range1M
0.56
Range3M
2.14
Rel. volume
0.69
Price X volume
62.39K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Cingulate Inc. Common Stock | CING | Biotechnology | 6.85 | 20.85M | 6.53% | n/a | 10.72% |
| DOMH | DOMH | Biotechnology | 3.21 | 20.15M | 7.72% | n/a | 7.66% |
| JSPR | JSPR | Biotechnology | 1.31 | 19.79M | -5.07% | n/a | 2.31% |
| RenovoRx Inc. Common Stock | RNXT | Biotechnology | 0.8002 | 19.19M | 1.27% | n/a | 0.00% |
| Inhibikase Therapeutics Inc. | IKT | Biotechnology | 1.89 | 18.85M | 0.53% | n/a | 3.49% |
| NRXP | NRXP | Biotechnology | 1.73 | 18.60M | 1.76% | n/a | -46.73% |
| IO Biotech Inc. Common Stock | IOBT | Biotechnology | 0.28 | 18.45M | -6.82% | n/a | 2.23% |
| PLUR | PLUR | Biotechnology | 3.37 | 18.43M | 2.74% | n/a | 30845.83% |
| Cue Biopharma Inc | CUE | Biotechnology | 0.301 | 18.12M | 0.40% | n/a | 52.09% |
| Enveric Biosciences Inc | ENVB | Biotechnology | 1.99 | 17.75M | 2.31% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6001 | 11.60M | -5.42% | n/a | 58.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 3.98 | 6.06M | -4.33% | n/a | 204.46% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.47 | 3.75M | -0.67% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.39 | 3.71M | -1.76% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.46 | 1.36M | 2.93% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.008 | 737.72K | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.03 | 0.53 | Expensive |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.50 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 121.40 | 72.80 | Riskier |
| Debt to Equity | 0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 19.07M | 3.66B | Emerging |